PT1076657E - Novos hidroxi-indoles, sua utilizacao como inibidores da fosfodiesterase 4 e processo para a sua producao - Google Patents

Novos hidroxi-indoles, sua utilizacao como inibidores da fosfodiesterase 4 e processo para a sua producao

Info

Publication number
PT1076657E
PT1076657E PT99920779T PT99920779T PT1076657E PT 1076657 E PT1076657 E PT 1076657E PT 99920779 T PT99920779 T PT 99920779T PT 99920779 T PT99920779 T PT 99920779T PT 1076657 E PT1076657 E PT 1076657E
Authority
PT
Portugal
Prior art keywords
indoles
phosphodiesterase
inhibitors
production
new hydroxy
Prior art date
Application number
PT99920779T
Other languages
English (en)
Inventor
Sabine Heer
Norbert Hofgen
Hildegard Poppe
Ute Egerland
Degenhard Marx
Stefan Szelenyi
Thomas Kronbach
Emmanuel Polymeropoulos
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19818964A external-priority patent/DE19818964A1/de
Priority claimed from DE1999117504 external-priority patent/DE19917504A1/de
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of PT1076657E publication Critical patent/PT1076657E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
PT99920779T 1998-04-28 1999-04-24 Novos hidroxi-indoles, sua utilizacao como inibidores da fosfodiesterase 4 e processo para a sua producao PT1076657E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19818964A DE19818964A1 (de) 1998-04-28 1998-04-28 Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
DE1999117504 DE19917504A1 (de) 1999-04-17 1999-04-17 Verwendung von Hydroxyindolen, die Inhibitoren der Phosphodiesterase 4 sind, zur Therapie chronisch obstruktiver Lungenerkrankungen

Publications (1)

Publication Number Publication Date
PT1076657E true PT1076657E (pt) 2004-11-30

Family

ID=26045814

Family Applications (2)

Application Number Title Priority Date Filing Date
PT04018391T PT1475377E (pt) 1998-04-28 1999-04-24 Derivados de indole e sua utilização como inibidores da fosfodiesterase 4
PT99920779T PT1076657E (pt) 1998-04-28 1999-04-24 Novos hidroxi-indoles, sua utilizacao como inibidores da fosfodiesterase 4 e processo para a sua producao

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT04018391T PT1475377E (pt) 1998-04-28 1999-04-24 Derivados de indole e sua utilização como inibidores da fosfodiesterase 4

Country Status (28)

Country Link
US (8) US6251923B1 (pt)
EP (2) EP1475377B1 (pt)
JP (2) JP3842043B2 (pt)
KR (1) KR100448748B1 (pt)
CN (1) CN1234705C (pt)
AR (1) AR016236A1 (pt)
AT (2) ATE330955T1 (pt)
AU (1) AU748403B2 (pt)
BG (1) BG65023B1 (pt)
BR (1) BR9910029A (pt)
CY (1) CY1105075T1 (pt)
CZ (1) CZ20003985A3 (pt)
DE (2) DE59913617D1 (pt)
DK (2) DK1076657T3 (pt)
ES (2) ES2222706T3 (pt)
HK (1) HK1035183A1 (pt)
HU (1) HUP0101625A3 (pt)
IL (2) IL138847A0 (pt)
NO (1) NO321867B1 (pt)
NZ (1) NZ507406A (pt)
PL (1) PL198983B1 (pt)
PT (2) PT1475377E (pt)
SI (2) SI1475377T1 (pt)
SK (1) SK286192B6 (pt)
TR (1) TR200003130T2 (pt)
TW (1) TW530048B (pt)
UA (1) UA59443C2 (pt)
WO (1) WO1999055696A1 (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE19946301A1 (de) 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
IL138847A0 (en) * 1998-04-28 2001-10-31 Dresden Arzneimittel New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
DE19924138A1 (de) 1999-05-26 2000-11-30 Henkel Kgaa Lösbare Klebeverbindungen
US6469006B1 (en) * 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
DE19951599A1 (de) * 1999-10-27 2001-05-23 Henkel Kgaa Verfahren zur adhesiven Trennung von Klebeverbunden
IT1315267B1 (it) * 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
US6573262B2 (en) 2000-07-10 2003-06-03 Bristol-Myers Sqibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
IT1318641B1 (it) 2000-07-25 2003-08-27 Novuspharma Spa Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale.
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
DE10037884A1 (de) * 2000-08-03 2002-02-21 Henkel Kgaa Verfahren zur beschleunigten Klebstoffaushärtung
TWI323658B (en) * 2001-12-06 2010-04-21 Nat Health Research Institutes Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
US7752681B2 (en) 2002-05-24 2010-07-13 Michel Licensing, Inc. Article of clothing with wicking portion
UA78999C2 (en) * 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
TW200400177A (en) 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
US20040038958A1 (en) * 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
CN1325490C (zh) 2002-08-01 2007-07-11 埃尔比昂股份公司 制备高纯度羟基吲哚基乙醛酰胺的方法
UA82323C2 (uk) * 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
DE10253426B4 (de) * 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10318609A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318610A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
DE10318611A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
WO2004098606A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and shuil-1r ii
US7205299B2 (en) * 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect
US7211588B2 (en) * 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
AU2004270733B2 (en) 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
WO2005062851A2 (en) * 2003-12-22 2005-07-14 Pappolla Miguel A Indole-3-propionamide and derivatives thereof
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
JPWO2006041121A1 (ja) * 2004-10-13 2008-05-15 協和醗酵工業株式会社 慢性皮膚疾患の治療および/または予防剤
WO2006041120A1 (ja) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. 医薬組成物
US20060110462A1 (en) * 2004-11-08 2006-05-25 Pavlos Papadopoulos Nanoparticulate compositions of tubulin inhibitor compounds
TW200738677A (en) * 2005-06-27 2007-10-16 Elbion Ag Nitro-substituted hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512676A (ja) 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ムスカリン性受容体アンタゴニストの医薬組成物
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
KR20080114688A (ko) 2006-01-13 2008-12-31 와이어쓰 5-히드록시트립타민 수용체에 대한 리간드로서의 술포닐 치환된 1h-인돌
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CN102772411A (zh) 2006-07-05 2012-11-14 奈科明有限责任公司 用于治疗炎症性肺部疾病的HMG-CoA还原酶抑制剂与磷酸二酯酶4抑制剂的组合
CA2660704A1 (en) 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2091532A1 (en) * 2006-11-28 2009-08-26 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
AU2007334541A1 (en) * 2006-12-13 2008-06-26 Gilead Sciences, Inc. Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (AISTM's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
JP2010523695A (ja) * 2007-04-11 2010-07-15 アルコン リサーチ, リミテッド アレルギー性鼻炎およびアレルギー性結膜炎を処置するためのTNFαのインヒビターおよび抗ヒスタミン薬の使用
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2010300421B2 (en) * 2009-10-01 2014-01-23 Alcon Research, Ltd. Olopatadine compositions and uses thereof
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
US20200254070A1 (en) 2018-12-28 2020-08-13 Regeneron Pharmaceuticals, Inc. Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors
US11674450B1 (en) 2021-12-13 2023-06-13 Pratt & Whitney Canada Corp. System and method for synthesizing engine thrust

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870162A (en) * 1954-04-28 1959-01-20 Upjohn Co Production of certain tryptamines and compounds produced in the process
NL100127C (pt) 1954-04-28
US2825734A (en) * 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
US2930797A (en) 1957-11-22 1960-03-29 Upjohn Co 2-alkyl-3-indoleglyoxylamides
GB944443A (pt) 1959-09-25 1900-01-01
US3028393A (en) 1960-05-11 1962-04-03 Upjohn Co Novel 1-(3-indoyl)-1, 2-alkanediols and substituted hydroxymethyl 3-in-dolyl ketones
US3196162A (en) * 1961-03-13 1965-07-20 Merck & Co Inc Indolyl aliphatic acids
US3271416A (en) * 1961-10-24 1966-09-06 Merck & Co Inc Indolyl aliphatic acids
US3259622A (en) * 1962-09-07 1966-07-05 Merck & Co Inc 1-benzyl-3-indolyl-alpha-haloalkyl and alkylidenyl acetic acids
US3238215A (en) * 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
US3342834A (en) 1964-03-02 1967-09-19 Merck & Co Inc Indolyl alkenoic acids
US3821387A (en) 1965-10-23 1974-06-28 Robins Co Inc A H The treatment of parkinsonism with 3-(omega-substituted alkyl)-indoles
US3459770A (en) 1966-12-07 1969-08-05 American Home Prod Indoleglyoxyloylpyrroles
US3527261A (en) 1968-11-12 1970-09-08 Babcock & Wilcox Co Tube guide apparatus
US3578669A (en) 1969-09-16 1971-05-11 Sterling Drug Inc 1-((2 - substituted - 3 - indolyl) - lower-alkanoyl) - cycloalkyl - lower-alkylpiperidines and 1 - ((2 - hydroxymethyl-3 - indolyl)-lower-alkayl)-cycloalkyl-lower-alkylpiperidines
US5192770A (en) 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
AU672224B2 (en) * 1992-08-06 1996-09-26 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and whichhave antitumor properties
WO1994012461A1 (en) 1992-12-02 1994-06-09 Pfizer Inc. Catechol diethers as selective pdeiv inhibitors
DE69329894T2 (de) * 1992-12-08 2001-05-03 Ss Pharmaceutical Co., Ltd. Arylamidderivate
US5424329A (en) 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
US5489586A (en) 1994-03-07 1996-02-06 Warner-Lambert Company Method for treating inflammatory disease in humans
WO1996004266A2 (de) 1994-08-03 1996-02-15 Asta Medica Aktiengesellschaft Indol-, indazol-, pyridopyrrol- und pyridopyrazol-derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender wirkung
DE19511916A1 (de) 1994-08-03 1996-02-08 Asta Medica Ag Neue N-Benzylindol- und Benzopyrazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
TW429148B (en) 1995-10-27 2001-04-11 Pfizer Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
JP2000516210A (ja) 1996-07-12 2000-12-05 ロイコサイト,インコーポレーテッド ケモカインレセプターアンタゴニストとその使用方法
CA2264020A1 (en) 1996-08-26 1998-03-05 Jean Bemis Inhibitors of phospholipase enzymes
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
IL138847A0 (en) * 1998-04-28 2001-10-31 Dresden Arzneimittel New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
IT1315267B1 (it) 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale

Also Published As

Publication number Publication date
BR9910029A (pt) 2000-12-26
HUP0101625A3 (en) 2002-12-28
CY1105075T1 (el) 2010-03-03
EP1475377B1 (de) 2006-06-21
ATE330955T1 (de) 2006-07-15
US6602890B2 (en) 2003-08-05
EP1475377A8 (de) 2005-01-19
JP2006249091A (ja) 2006-09-21
IL138847A (en) 2006-08-20
KR100448748B1 (ko) 2004-09-18
SK15752000A3 (sk) 2001-08-06
AR016236A1 (es) 2001-06-20
EP1076657B1 (de) 2004-08-04
HUP0101625A2 (hu) 2001-11-28
EP1475377A1 (de) 2004-11-10
US6613794B2 (en) 2003-09-02
SI1076657T1 (en) 2004-12-31
US6545158B2 (en) 2003-04-08
DE59910142D1 (de) 2004-09-09
US20040220183A1 (en) 2004-11-04
US7161009B2 (en) 2007-01-09
CZ20003985A3 (cs) 2001-09-12
AU748403B2 (en) 2002-06-06
NO20005454D0 (no) 2000-10-27
PL198983B1 (pl) 2008-08-29
US20020119971A1 (en) 2002-08-29
ATE272631T1 (de) 2004-08-15
US6251923B1 (en) 2001-06-26
SK286192B6 (sk) 2008-05-06
DK1076657T3 (da) 2004-11-08
AU3822999A (en) 1999-11-16
US20020137745A1 (en) 2002-09-26
DK1475377T3 (da) 2006-10-23
SI1475377T1 (sl) 2006-12-31
ES2222706T3 (es) 2005-02-01
HK1035183A1 (en) 2001-11-16
BG104842A (en) 2001-10-31
TW530048B (en) 2003-05-01
US6545025B2 (en) 2003-04-08
US20020115651A1 (en) 2002-08-22
ES2262072T3 (es) 2006-11-16
BG65023B1 (bg) 2006-12-29
EP1076657A1 (de) 2001-02-21
CN1234705C (zh) 2006-01-04
US20030134876A1 (en) 2003-07-17
PT1475377E (pt) 2006-11-30
JP3842043B2 (ja) 2006-11-08
KR20010043106A (ko) 2001-05-25
IL138847A0 (en) 2001-10-31
CN1307575A (zh) 2001-08-08
DE59913617D1 (de) 2006-08-03
WO1999055696A1 (de) 1999-11-04
PL343569A1 (en) 2001-08-27
US20020111351A1 (en) 2002-08-15
NZ507406A (en) 2002-11-26
TR200003130T2 (tr) 2001-01-22
NO321867B1 (no) 2006-07-17
NO20005454L (no) 2000-12-07
USRE38624E1 (en) 2004-10-12
JP2002513017A (ja) 2002-05-08
UA59443C2 (uk) 2003-09-15

Similar Documents

Publication Publication Date Title
PT1076657E (pt) Novos hidroxi-indoles, sua utilizacao como inibidores da fosfodiesterase 4 e processo para a sua producao
BR9804243B1 (pt) processo para produÇço de Ácido acrÍlico.
PT1124810E (pt) Derivados 2-amino-tiazole, processo para a sua preparacao e sua utilizacao como agentes anti-tumorais
BR9804378B1 (pt) compostos, processo para sua produção e uso.
BR9500835A (pt) Processo para produção de poliisobutenos
BR9911129B1 (pt) n-alquiluretanos (i) de fructanos, seu uso, bem como sua composiÇço e processo para sua produÇço.
BR9802374A (pt) Artigo absorvente e processo de produção para o mesmo
EE9700354A (et) Trombiini uued inhibiitorid, nende saamine ja kasutamine
PT950657E (pt) Carbazoles substituidos, processo para a sua preparacao, e sua utilizacao como inibidores de spla2
PT1330455E (pt) Novos 7-azaindoles sua utilizacao como inibidores da fosfodiesterase 4 e processos para a sua producao
PT1038899E (pt) PROMOTOR DE ADESAO PARA REFORCOS TêXTEIS INTERNOS PROCESSO PARA A SUA PRODUCAO E A SUA UTILIZACAO
BR9502774A (pt) Inibidor de combustão total fuselagens de aeronaves e processo para sua produção.
BR9708336A (pt) Diidrato de eprosartan e processo para sua produção e formulação
PT770687E (pt) Processo para a producao de nicotinamida
BR9602789A (pt) Processo para a produção de aminas aromáticas e catalisador
ID23957A (id) Proses produksi amina aromatik
PT1015433E (pt) 1,2,3,4,5,6-hexa-hidro-2,6-metano-3-benzazocin-10-ois substituidos processo para a sua producao e sua utilizacao como medicamentos
BR9714066B1 (pt) processo para a preparaÇço de derivados de tiazol, bem como intermediÁrios e processos para sua preparaÇço.
PT1472221E (pt) Indois substituidos, processo para a sua producao e utilizacao na inibicao de dor
BR9607413A (pt) Processo para produçao de pentafluoretano e tetrafluorcloroetano
PT1210318E (pt) Processo para producao de adrenalina
PT970077E (pt) Processo melhorado para a producao de tiazolidinedionas e novas tiazolidinedionas
BR9804873A (pt) Processo para a produ-Æo de ironas
BR9503611A (pt) Processo para a produçao contínua de compostos nitroaromáticos
BR9608672A (pt) Aço ferrítico e processo para sua fabricação e utilização